Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma

What we are studying

This study is for patients with ependymoma. Ependymoma is a type of cancer that occurs in the brain. This slow-growing tumor begins in cells that line the fluid-filled spaces of the brain (called ventricles) or the fluid-filled space down the center of the spinal cord (the central canal). The current standard of treatment for newly diagnosed ependymoma includes surgery to remove as much of the tumor as possible, and radiation therapy (the use of high-dose x-rays to kill cancer cells). The purpose of this study is to see if giving chemotherapy after surgery and radiation therapy will work better to get rid of the tumor and/or keep it from coming back than treatment with standard therapy. Treatment with chemotherapy is experimental. We also want to study the effects of surgery, radiation therapy and chemotherapy on learning, thinking, hearing and the production of hormones (substances made in the brain that affect growth and development). Additionally, we want to study tumor tissue and blood for possible genetic and biologic factors related to ependymoma.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 1 - 20

Eligibility Criteria

  • Newly diagnosed with ependymoma

What is involved

  • Length of treatment will range from about 6 to 18 weeks
  • Follow-Up will last for 10 years



Contact Information

Study Coordinator
Graham Keyes

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.